Quarterly report pursuant to Section 13 or 15(d)

Business (Details)

v3.19.2
Business (Details)
3 Months Ended 6 Months Ended 12 Months Ended
Mar. 08, 2019
$ / shares
shares
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
$ / shares
shares
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
product
Subsequent Event [Line Items]              
Net loss   $ (6,223,099)   $ (6,007,476) $ (13,677,147) $ (9,890,319)  
Net cash used in operating activities         (9,838,855) (614,096)  
Accumulated deficit   (111,895,217)     (111,895,217)   $ (98,218,070)
Cash and cash equivalents   $ 9,386,865   $ 2,179,775 $ 9,386,865 $ 2,179,775 $ 10,646,301
Sale of stock (in shares) | shares 363,637            
Purchase price (in dollars per share) | $ / shares $ 5.50            
Neurological Clinical And Preclinical Stage Compounds              
Subsequent Event [Line Items]              
Number of products in development | product             3
Preclinical Pediatric Orphan Rare Disease Compound              
Subsequent Event [Line Items]              
Number of products in development | product             1
Underwritten Public Offering | Common stock              
Subsequent Event [Line Items]              
Sale of stock (in shares) | shares     1,818,182        
Purchase price (in dollars per share) | $ / shares     $ 5.50        
Net proceeds     $ 9,000,000        
Armistice | Underwritten Public Offering | Common stock              
Subsequent Event [Line Items]              
Sale of stock (in shares) | shares     363,637